Javascript must be enabled to continue!
Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome
View through CrossRef
Background: Letrozole, an aromatase inhibitor has been regarded as the first line drug for ovulation induction in anovulatory PCOS patients because of its monofollicular growth and there is no chance of hyperstimulation by letrozole. Traditional protocol of letrozole includes administration of letrozole for 5 days in first half of follicular phase which induces ovulation in 61.7% cases. Few recent studies have shown that extended letrozole protocol causes more follicles to grow and induces more ovulation than the traditional protocol. The aim was to compare the effects of low dose-extended letrozole protocol and double dose-short letrozole protocol for ovulation induction in infertile PCOS patients.Methods: A randomized controlled trial (RCT) was conducted in the department of reproductive endocrinology and Infertility at Bangabandhu Sheikh Mujib Medical University (BSMMU) on seventy infertile polycystic ovary syndrome patients. Low dose-extended letrozole group or experimental group received tablet letrozole 2.5 mg daily for 10 days and double dose-short letrozole group or control group received tab. Letrozole 5 mg daily for 5 days starting from the 2nd day of menstrual cycle or withdrawal bleeding. The ovarian response was assessed by folliculometry on day 12 of menstrual cycle by transvaginal sonography for measurement of total number of growing follicles, biggest follicle size and endometrial thickness. Mid luteal serum progesterone was measured on day 21-23 to confirm ovulation.Results: The mean number of growing follicle was 1.440.95 versus 0.990.65 in low dose-extended letrozole group and double dose-short letrozole group respectively generating p value of 0.001. The mean size of the dominant follicle at day 12 was greater in low dose-extended letrozole group than the other displaying 17.69±3.63 mm and 16.6±3.49 mm respectively but the difference was not statistically significant. The number of ovulating patients was greater in low dose-extended letrozole group (76.5% versus 71.9%), but without significant statistical difference. Pregnancy rate was insignificantly greater in low dose-extended letrozole group (23.5% versus 18.8%) as well.Conclusions: Low dose-extended letrozole protocol produces more multifollicular growth and larger size dominant follicle with a trend to raise the ovulation rate and pregnancy rate, though insignificantly.
Title: Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome
Description:
Background: Letrozole, an aromatase inhibitor has been regarded as the first line drug for ovulation induction in anovulatory PCOS patients because of its monofollicular growth and there is no chance of hyperstimulation by letrozole.
Traditional protocol of letrozole includes administration of letrozole for 5 days in first half of follicular phase which induces ovulation in 61.
7% cases.
Few recent studies have shown that extended letrozole protocol causes more follicles to grow and induces more ovulation than the traditional protocol.
The aim was to compare the effects of low dose-extended letrozole protocol and double dose-short letrozole protocol for ovulation induction in infertile PCOS patients.
Methods: A randomized controlled trial (RCT) was conducted in the department of reproductive endocrinology and Infertility at Bangabandhu Sheikh Mujib Medical University (BSMMU) on seventy infertile polycystic ovary syndrome patients.
Low dose-extended letrozole group or experimental group received tablet letrozole 2.
5 mg daily for 10 days and double dose-short letrozole group or control group received tab.
Letrozole 5 mg daily for 5 days starting from the 2nd day of menstrual cycle or withdrawal bleeding.
The ovarian response was assessed by folliculometry on day 12 of menstrual cycle by transvaginal sonography for measurement of total number of growing follicles, biggest follicle size and endometrial thickness.
Mid luteal serum progesterone was measured on day 21-23 to confirm ovulation.
Results: The mean number of growing follicle was 1.
440.
95 versus 0.
990.
65 in low dose-extended letrozole group and double dose-short letrozole group respectively generating p value of 0.
001.
The mean size of the dominant follicle at day 12 was greater in low dose-extended letrozole group than the other displaying 17.
69±3.
63 mm and 16.
6±3.
49 mm respectively but the difference was not statistically significant.
The number of ovulating patients was greater in low dose-extended letrozole group (76.
5% versus 71.
9%), but without significant statistical difference.
Pregnancy rate was insignificantly greater in low dose-extended letrozole group (23.
5% versus 18.
8%) as well.
Conclusions: Low dose-extended letrozole protocol produces more multifollicular growth and larger size dominant follicle with a trend to raise the ovulation rate and pregnancy rate, though insignificantly.
Related Results
P-604 A novel ovulation induction regimen in women with polycystic ovary syndrome resistant to letrozole: letrozole stair-step duration regimen
P-604 A novel ovulation induction regimen in women with polycystic ovary syndrome resistant to letrozole: letrozole stair-step duration regimen
Abstract
Study question
Whether the letrozole stair-step duration regimen is effective and time-saving for ovulation induction i...
P-605 The predictive role of follicle-stimulating hormone receptor polymorphism on letrozole resistance in women with polycystic ovary syndrome
P-605 The predictive role of follicle-stimulating hormone receptor polymorphism on letrozole resistance in women with polycystic ovary syndrome
Abstract
Study question
Whether follicle stimulating hormone receptor (FSHR) polymorphism can predict letrozole resistance in wo...
Melatonin enhances ovarian response in infertile women with polycystic ovary syndrome: A randomized controlled trial.
Melatonin enhances ovarian response in infertile women with polycystic ovary syndrome: A randomized controlled trial.
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Anovulation, decreased Oocyte quality and low endometrial receptivity are ...
Update on Polycystic Ovary Syndrome
Update on Polycystic Ovary Syndrome
ABSTRACT
Purpose
Polycystic ovary syndrome is the most common endocrine disorder in reproductive-aged women. Polycystic ovary syndrome affects ap...
Comparison Of Lactobacillus Plantarum, Lactobacillus Mucosae And Lactobacillus Farciminis Bacteria Between Polycystic Ovary Syndrome And Non Polycystic Ovary Syndrome Students At Medical Faculty Of Andalas University
Comparison Of Lactobacillus Plantarum, Lactobacillus Mucosae And Lactobacillus Farciminis Bacteria Between Polycystic Ovary Syndrome And Non Polycystic Ovary Syndrome Students At Medical Faculty Of Andalas University
Background: Polycystic Ovary Syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and morphological features of polycystic ovaries. It is associa...
Comparison of letrozole and clomiphene citrate efficacy in terms of ovulation induction and pregnancy rate.
Comparison of letrozole and clomiphene citrate efficacy in terms of ovulation induction and pregnancy rate.
Objective: To compare the efficacy of Letrozole and clomiphene citrate in Patients of Anovulation polycystic ovarian syndrome with Infertility. Study Design: Randomized Controlled ...
Gremlin-1 level in polycystic ovary syndrome and its clinical correlations; A case control study
Gremlin-1 level in polycystic ovary syndrome and its clinical correlations; A case control study
Objective: To evaluate the involvement of the level of Gremlin-1 in serum and follicular fluid in the diagnosis of polycystic ovary syndrome.Methods: The case-control study was con...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

